Henderson Jane 4
4 · Apogee Therapeutics, Inc. · Filed May 4, 2026
Research Summary
AI-generated summary of this filing
Apogee Therapeutics (APGE) CFO Jane Henderson Sells Shares
What Happened
Jane Henderson, Chief Financial Officer of Apogee Therapeutics (APGE), sold a total of 2,000 shares in open-market transactions on May 1, 2026, generating approximately $164,080 in proceeds. The sales were reported as three lots: 811 shares at a weighted avg price of $81.02 ($65,707), 900 shares at $82.60 ($74,340), and 289 shares at $83.16 ($24,033). These were outright sales (S) and are typically routine rather than a direct buy signal.
Key Details
- Transaction date: May 1, 2026; Form 4 filed May 4, 2026 (within the 2-business-day filing window).
- Lots and reported weighted-average prices/values:
- 811 shares @ $81.02 = $65,707 (prices ranged $80.640–$81.260) [F2]
- 900 shares @ $82.60 = $74,340 (prices ranged $82.040–$82.995) [F3]
- 289 shares @ $83.16 = $24,033 (prices ranged $83.090–$83.190) [F4]
- Total shares sold: 2,000; total proceeds: ~$164,080.
- Notable footnote: At least one transaction was executed pursuant to a Rule 10b5-1 trading plan adopted Sept 2, 2025 [F1].
- Shares owned after the transaction: not provided in the material supplied.
Context
Sales by executives can be for many reasons (diversification, taxes, scheduled plans). The presence of a 10b5-1 plan means at least part of these trades were prearranged and may be less informative about the CFO’s near-term view of the company. Purchases generally carry more weight as a bullish signal; this filing documents routine insider selling.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-05-01$81.02/sh−811$65,707→ 174,560 total - Sale
Common Stock
[F1][F3]2026-05-01$82.60/sh−900$74,340→ 173,660 total - Sale
Common Stock
[F1][F4]2026-05-01$83.16/sh−289$24,033→ 173,371 total
Footnotes (4)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.640 to $81.260, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.040 to $82.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.090 to $83.190, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.